SNPMiner Trials (Home Page)
Report for SNP rs9679162
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 Randomized, Controlled, Open Label, Clinical Trial for Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in Hepatocellular Carcinoma Patients With GALNT14-rs9679162-non-TT Genotype
TACE against HCC is the standard of care for BCLC stage B patients. In this exploratory study, the investigators assess the efficacy of TACE with or without adagloxad simolenin/OBI-821 treatment in GALNT14 "non-TT" HCC population.
NCT03608878 Hepatocellular Carcinoma Biological: adagloxad simolenin/OBI-821 Procedure: TACE MeSH:Carcinoma Carcinoma, Hepatocellular
HPO:Carcinoma Hepatocellular carcinoma
5. Child-Pugh functional class A or B. 6. GALNT14- rs9679162 "non TT" genotype 7.
Primary Outcomes
Description: time-to-intrahepatic total tumor volume progression
Measure: time-to-ITTVP Time: From enrollment till 36 months of follow-up.